Network Management Core (NEMO) for the Pulmonary Trials cooperative (PTC) (RETHINC)
Grant
Overview
abstract
-
A 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily in symptomatic current and former smokers with respiratory symptoms despite preserved spirometry as defined by CAT = 10 and post-bronchodilator FEV1/FVC ratio =0.70, respectively.
date/time interval
awarded by